PVI
EPZM

Pura Vida Investments’s Epizyme, Inc EPZM Stock Holding History

Pura Vida Investments’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100,000
Closed -$1.51M – 96
2017
Q2 		$1.51M Buy
+100,000
New +$1.51M 0.6% 44

Other funds holding EPZM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Pura Vida Investments's EPZM Position: Q3 2017 in Review

Pura Vida Investments sold out of Epizyme, Inc (EPZM) in Q3 2017, closing a stake of 100,000 shares — an estimated $1.51M sold.

Pura Vida Investments first reported a position in EPZM in Q2 2017 and held it in 1 quarter. The position peaked at $1.51M in Q2 2017. 104 funds tracked by Wall St. Rank hold EPZM as of Q3 2017.

  • Pura Vida Investments reported no remaining Epizyme, Inc position as of Q3 2017 after selling out during the quarter.
  • Pura Vida Investments sold 100,000 Epizyme, Inc shares in Q3 2017, an estimated $1.51M.
  • Pura Vida Investments first reported a position in Epizyme, Inc in Q2 2017 and held it in 1 quarter.
  • Pura Vida Investments's Epizyme, Inc position peaked at $1.51M in Q2 2017.
  • 104 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2017.

Based on Pura Vida Investments's 13F filing for Q3 2017, filed 14 Nov 2017.